Precision medicine promises to tailor health care to the individual. But what happens when entire communities are left out of ...

Return on Assets (ROA): Ionis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing ...

Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

This month: good news for java lovers, a how-to guide on migraine and CVD, medically tailored meals for HF, and more.

Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.